Praxis Precision Medicines, Inc.PRAXEarnings & Financial Report
Wyeth Pharmaceuticals Inc. was a pharmaceutical company until it was purchased by Pfizer in 2009. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother. Its headquarters moved to Collegeville, Pennsylvania, and Madison, New Jersey, before its headquarters were consolidated with Pfizer's in New York City after the 2009 merger.
Revenue
$7.5M
Gross Profit
N/A
Operating Profit
$-64.0M
Net Profit
$-58.7M
Gross Margin
N/A
Operating Margin
-857.0%
Net Margin
-786.3%
YoY Growth
1349.1%
EPS
$-2.88
Praxis Precision Medicines, Inc. Q4 FY2024 Financial Summary
Praxis Precision Medicines, Inc. reported revenue of $7.5M (up 1349.1% YoY) for Q4 FY2024, with a net profit of $-58.7M (down 118.3% YoY) (-786.3% margin).
Key Financial Metrics
| Total Revenue | $7.5M |
|---|---|
| Net Profit | $-58.7M |
| Gross Margin | N/A |
| Operating Margin | -857.0% |
| Report Period | Q4 FY2024 |
Praxis Precision Medicines, Inc. Annual Revenue by Year
Praxis Precision Medicines, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2022 | $0 |
Praxis Precision Medicines, Inc. Quarterly Revenue & Net Profit History
Praxis Precision Medicines, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-88.9M | N/A |
| Q3 FY2025 | $0 | — | $-73.9M | N/A |
| Q2 FY2025 | $0 | — | $-71.1M | N/A |
| Q1 FY2025 | $0 | — | $-69.3M | N/A |
| Q4 FY2024 | $7.5M | +1349.1% | $-58.7M | -786.3% |
| Q4 FY2022 | $0 | — | $-41.2M | N/A |
| Q3 FY2022 | $0 | — | $-43.9M | N/A |
| Q2 FY2022 | $0 | — | $-60.2M | N/A |
Income Statement
| Q2 2022 | Q3 2022 | Q4 2022 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $7.5M | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | 1349.1% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2022 | Q3 2022 | Q4 2022 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $180.4M | $136.9M | $115.1M | $483.1M | $478.7M | $452.8M | $396.4M | $937.9M |
| Liabilities | $41.5M | $31.7M | $39.0M | $37.7M | $39.5M | $48.6M | $52.9M | $59.8M |
| Equity | $138.9M | $105.2M | $76.1M | $445.4M | $439.2M | $404.2M | $343.5M | $878.1M |
Cash Flow
| Q2 2022 | Q3 2022 | Q4 2022 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-57.2M | $-44.9M | $-28.8M | $-56.1M | $-53.0M | $-54.7M | $-65.1M | $-76.3M |